A novel dendritic-like cell subset termed L-DC was recently identified in murine spleen based on marker expression of a homogeneous cell population derived from long-term culture of neonatal spleen. The function of L-DC is distinct from other splenic dendritic and myeloid cell subsets because of their high endocytic capacity and their ability to cross-present antigen to CD8 + T cells. This paper shows the subset to be unique to spleen and blood, with a similar, but possibly functionally distinct subset also present in bone marrow. The prevalence of the subset is low; 6% of all dendritic and myeloid cells in the spleen and~5% in blood. However, they are a distinct cell type on the basis of marker expression, and endocytic and T-cell stimulatory capacity. Attempts to identify an enriched population of these cells in mutant mouse strains with reported increases in myelopoiesis showed either a lack of L-DC or an altered phenotype reflective of the phenotype of the mouse strain.
Introduction
The importance of dendritic cells (DC) in the immune system as the mediators between innate and adaptive immunity has only recently become apparent. As a result, this field of study is relatively new and DC are emerging to be a complex cell type with extensive variability in phenotype and function. Murine DC can largely be divided into three types: migratory DC, conventional (c)DC and plasmacytoid (p)DC. Migratory DC, such as Langerhans cells, develop in the periphery and migrate to lymph nodes following encounter with antigen to activate T cells [1, 2] . Conventional DC are blood-derived, reside in the spleen, and can be further divided into subsets based on marker expression. Functional definition of the cDC subsets, namely CD8a + cDC (CD11c ), has proven difficult. CD8a + cDC are generally thought to be crosspresenting cells inducing a CD8 + T-cell response [3] with an ability to induce Th1 CD4 + T cells through production of the Th1-inducing cytokine interleukin (IL)-12, and can also produce the type I interferons IFN-a and IFN-b [4] [5] [6] . CD8a
À cDC are classified as Th2-inducing cells [4, 5] ; however, they have also been reported to produce IL-12 as well as IFN-c [6, 7] , and have cross-presenting capacity in some model infections [8] . Plasmacytoid DC are an IFN-a-producing subset involved in virus clearance at the level of the innate immune response, later maturing to become DC capable of inducing adaptive immune responses [9] .
This laboratory has identified a dendritic-like subset that develops as a homogeneous population of cells in vitro following culture of whole spleen from neonatal mice [10] . These long-term cultures maintain production of cells over a period of years, through development of large mature cells along with progenitors and precursors, which are maintained in the cultures. Long-term culture DC (L-DC) have a characteristic phenotype as CD11c lo CD11b hi CD8a À MHC-II À cells, which are very large in terms of forward scatter (FSC) when examined using flow cytometry [10] . On the basis of the distinct marker expression and size of L-DC, we recently reported an in vivo equivalent dendritic-like cell with high endocytic and cross-presenting capacity in vitro [11] . The L-DC marker expression relative to other DC subsets as reported in Tan et al. [11] is summarized in Table 1 . Here, we characterize L-DC in terms of prevalence in relation to other known DC subsets in spleen and other tissues. Given their high CD11b expression, L-DC are thought to be of myeloid origin. To determine the effect of mutations affecting myelopoiesis on the relative prevalence of cDC, pDC and L-DC, we investigate their tissue distribution and lineage relationships and examine the prevalence of these cells in normal mouse lymphoid tissues and in two mutant strains of mice where myelopoiesis has been affected.
Materials and methods

Animals
Specific pathogen-free female C57BL/6J (CD45. , respectively] were obtained from the APF. Mice were housed and handled according to protocols approved by the Animal Experimentation Ethics Committee at the ANU and killed by cervical dislocation.
Tissue culture
DMEM was supplemented with 10% foetal calf serum (JRH Biosciences, Lenexa, KS, USA), 10 mM Hepes (JRH Biosciences), 2 mM L-glutamine (JRH Biosciences), 100 U/ml penicillin (JCSMR), 100 lg/ml streptomycin (JCSMR) and 5 9 10 À5 M 2-mercaptoethanol (BDH Ltd., Poole, United Kingdom). This is referred to as supplemented DMEM (sDMEM). Cells were maintained in 5% CO 2 in air and 97% humidity at 37°C. For estimation of cell number and viability, cells were stained with trypan blue (0.4%/saline; Gibco BRL, Grand Island, NY, USA).
Preparation of lymphoid cells ex vivo
For preparation of single cell suspensions, bone marrow (BM) was isolated from the femur of a C57BL/6J mouse. Marrow was flushed from the bone cavity by injection of DMEM by using a syringe equipped with a 26-G needle. Cells were dissociated by pipetting and resuspended in sDMEM. After sedimentation, red blood cells (RBC) were removed by lysis in RBC lysis buffer (140 mM NH 4 Cl, 17 mM Tris base in deionised water). Cells were then washed twice in sDMEM and counted. For preparation of thymocytes and cells from the mesenteric lymph node (MLN), tissues were dissociated by pressing through a fine mesh sieve. For isolation of splenocytes, dissected spleen was pressed through a fine mesh sieve. Cells were resuspended in sDMEM, RBC lysed and cells washed as described for BM. Cells were counted after the final wash.
For T-and B-cell depletion, splenocytes were incubated with 0.25 lg/ml biotinylated anti-CD19 antibody (eBiosciences, San Diego, CA, USA)/10 8 cells (B cells), and 0.2 lg/ml biotinylated anti-Thy1.2 antibody (eBiosciences)/10 8 cells (T cells) in 1 ml/10 8 cells for 10 min. on ice in labelling buffer (0.5%/2 mM EDTA/PBS). Cells were washed twice with labelling buffer and anti-biotin microbeads (Miltenyi Biotec, Auburn, CA, USA) were added at 13 ll beads/10 8 cells in 1 ml/10 8 cells and incubated for 25 min. on ice. Cells were washed once in labelling buffer and resuspended in 500 ll of the same buffer. The LS depletion column (Miltenyi Biotec) was prepared by placing it in a magnet (SuperMacs; Miltenyi Biotec) and washing once with 3 ml labelling buffer. The cell suspension was then run through the column and collected in a new tube, followed by three washes with 3 ml labelling buffer. Cells were pelleted and resuspended in sDMEM for counting and antibody staining.
Antibody staining of cells and analysis and sorting by using flow cytometry For staining,~5 9 10 5 cells were sedimented into the wells of a flexible 96-well polystyrene microtitre plate (Corning, Tewksbury, MA, USA). Cells were resuspended in anti-CD16/32 (FcBlock) prior to staining in a primary antibody cocktail. Where necessary, secondary reagents were added before resuspension in DMEM/1%FCS/0.1%NaN 3 before transfer to cluster tubes (Corning) for analysis by using a flow cytometer (Becton Dickinson LSRII, San Jose, CA, USA). Prior to analysis, propidium iodide (PI: 100 lg/ml) was added for dead cell discrimination. Background binding was determined by using isotype control antibodies corresponding to each fluorescence-conjugated antibody used, and gates were set by using this information as well as internal positive and negative cell subsets to identify specific staining. Analysis was performed using BD FACSDiva software (Becton Dickson) and Flow Jo software (Tristar, Phoenix, AZ, USA). For fluorescence-activated cell sorting, cells were processed as above before being sorted at the sorting facility at the JCSMR.
Endocytic capacity of cells
The in vivo endocytic capacity of isolated DC subsets was tested by using FITC-conjugated ovalbumin (OVA). OVA-FITC (10 mg/ml) was injected i.v. into mice in 300 ll HBSS. Mice were left for 24 hrs before sacrifice and spleen removal. Spleens were dissociated and stained with antibodies. 
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CFSE labelling
Cells were labelled with CFSE for analysis of reduction in label as a measure of cell division. Cells were washed and then resuspended in DMEM (100 ll/10 7 cells). One ll CFSE, final concentration 10 lg/ml, was added and vortexed immediately. Cells were incubated for 5 min. at room temperature with agitation before adding 1 ml sDMEM and washing twice.
OT-I and OT-II T-cell stimulation assays
Antigen-specific T-cell stimulation capacity of DC was assessed by using CD8 + T cells obtained from OT-I mice and CD4 + T cells obtained from OT-II mice. These mice express TCR transgenes specific for OVA presented on either MHC-I (OT-I) or MHC-II (OT-II). Hen egg lysozyme (HEL; SigmaAldrich, St. Louis, MO, USA) was used as a negative control antigen.
Dendritic cells were pulsed in vivo with either 0.5 mg HEL or 0.5 mg OVA administered through i.v. injection. After 24 hrs, spleen was collected and the DC subsets stained and sorted as described above. CD4 
Results
Identification of cells with CD11c lo
CD11b hi
CD8a
À MHC-II À phenotype in murine spleen, BM and blood As described previously by Tan et al. in 2011 [11] , the in vivo counterpart to L-DC represent a distinct subset of CD11c lo CD11b hi CD8a À MHC-II À cells in spleen compared with cDC, pDC and monocytes, and are distinguishable by the selected markers as well as by their characteristically large size. Each of the splenic DC subsets is identified here by using the same gating strategy (Fig. 1 ). This gating protocol was applied to BM ( Means AE SD were calculated for all animals tested (n = 7 for spleen, n = 6 for BM and MLN, and n = 2 for blood) and data are shown in Table 2 . L-DC represent the smallest subset of DC in spleen, comprising just 0.07 AE 0.02% of all spleen leucocytes (data not shown) and 5.86 AE 0.30% of all CD11c + and/or CD11b + dendritic/ myeloid cells ( Table 2 ). The most abundant subsets in spleen were CD8a À cDC and monocytes, representing equal proportions of the dendritic/myeloid fraction of spleen: 30.20 AE 13.05% for CD8a
À cDC and 31.00 AE 13.08% for monocytes. It is not clear whether this variation reflects natural variation between animals or experimental error related to preparation and staining. CD8a + cDC and p-preDC reflected similar proportions (~17%) of all dendritic/myeloid cells.
In BM, cells resembling L-DC represent the smallest subset amongst identified dendritic/myeloid cells with an average representation of 7 AE 1.5%. Plasmacytoid-preDC represent a very variable population, making up 12.67 AE 5% of dendritic/myeloid cells. Again, this could reflect variation between animals or between experiments. Monocytes were by far the largest subset in BM, representing 80.17 AE 5% of all dendritic/myeloid cells. No L-DC were detected in MLN. The DC subsets detected in blood were L-DC (5 AE 2%), p-preDC (12 AE 1%) and monocytes (82 AE 1%) in a composition similar to that observed in BM.
L-DC have a highly endocytic phenotype
It has already been established that, compared to cDC and monocytes, L-DC are highly endocytic when pulsed with antigen in vitro, and are capable of activating CD8 + T cells in a mixed lymphocyte reaction [11] . To further investigate their functional capacity in terms of their ability to take up antigen in vivo, mice received 3 mg FITCconjugated OVA i.v. Mice were killed 24 hrs later and spleens stained for DC subsets to determine OVA-FITC uptake. Figure 3A shows highest level of uptake by monocytes and L-DC (~90% of cells). Uptake by cDC was comparatively low (9% and 30% for CD8a + cDC and CD8a À cDC, respectively). In an attempt to distinguish L-DC from monocytes based on function, DC subsets were sorted from animals that had been pulsed with OVA antigen in vivo as described above. The sorted cells were then incubated with CFSE-stained CD4 + or CD8 + T cells from mice expressing OVA-specific TCR (OT-II or OT-I mice), respectively. APCs and T cells were co-cultured with or without 3 lg lipopolysaccharide (LPS) for 4 days before analysis of cell proliferation by flow cytometry. The T-cell proliferative response was therefore related to in vivo uptake capacity for antigen by each subset.
As shown in Figure 3B , the strongest effect on CD8 + OT-I T-cell proliferation was induced by L-DC, but only after culture in the presence of LPS. This suggests that L-DC are very capable activators of OT-I T cells, and are both accessible to blood-borne antigen and capable of high uptake compared with other subsets. In particular, whilst monocytes and L-DC have very similar marker expression ( and for L-DC, although the latter response was not improved by addition of LPS (Fig. 3C) .
Prevalence of L-DC in sanroque animals
To investigate possible sources of a higher yield of L-DC, we investigated their prevalence in mutant mouse strains. As L-DC are thought to derive from the myeloid lineage, two available mutant mouse strains with a known increase in myelopoiesis were investigated: sanroque [12] and Rag À/À . Both strains are on the same C57BL/6J genetic background as the wild-type (+/+) mice analysed above so that any perturbation in L-DC number in mutant strain would therefore be due entirely to the mutation.
Sanroque mice were developed by Prof. Chris Goodnow and Dr. Carola Vinuesa (JCSMR: ANU), and lack the ubiquitin ligase Roquin [12] . Mice homozygous for the mutation are labelled san/san. These mice have severe autoimmune disease, and all develop systemic lupus erythematosus. Mice are in a perpetual state of inflammation because of autoimmunity [13] and appear to have a higher prevalence of myeloid cells [12] . Consequently, it was thought that the sanroque mouse model may show an enriched population of L-DC, with or without other myeloid lineage cells.
The presence of L-DC in mutants was checked by staining for DC markers as for +/+ mice. Flow cytometry gates from the +/+ control were overlaid on to those for mutant mice. Circular gates, shown in Figure 4 , were then used to denote populations present in mutant, but not +/+ animals. Spleen (A), BM (B), and mesenteric (data not shown) and cervical LN (CLN) (C) were prepared for analysis. Cervical lymph nodes were taken from these animals because of their obvious enlargement. Figure 4 shows how the general profile of DC subsets in spleen, BM and CLN of san/san mice differs from that of +/+ mice. The CD11b hi MHC-II À population gated from the +/+ lo CD8a À cell subset has been classified as L-DC, and this population shows characteristic high FSC (data not shown). However, it appears that any L-DC have gained MHC-II expression in san/san mice, a phenotype that is possible because of the constitutive inflammatory state of san/san animals. Several other cell populations in san/san spleen also appear to have altered phenotypes, such as monocytes, which have gained MHC-II expression. Furthermore, pDC derived from the CD11c lo CD8a À gate have gained MHC-II, and perhaps low CD11b expression, which could represent activated pDC. L-DC are not present in BM of san/san mice in any significant number, such that their existence is debatable. As observed in +/+ mice, there is no detectable population of pDC; however, san/ san animals appear to have a significant population of p-preDC (Fig. 4B) . There is also increased representation of a CD11c À CD11b lo CD8a
À MHC-II À subset (Fig. 4B ) that may represent an expanded population of myeloid precursors. In san/san BM, monocytes dominate in cell number, representing roughly double the percentage present in +/+ animals ( Fig. 4B and Table 2 ). This reflects the previously observed increase in cells of the myeloid lineage in san/san mice [12] .
Dendritic cells subsets in MLN (data not shown) and CLN (Fig. 4C) 
CD8a
À MHC-II lo cells is present, which reflect activated myeloid DC in phenotype, and possibly activated L-DC, although their size on FSC is not as large as L-DC detected in +/+ spleen and BM, and cells also express MHC-II. Table 2 contains a summary of the percentage distribution of each identifiable dendritic and myeloid cell subset amongst total spleen, BM and CLN dendritic/myeloid cells. These data are based on mean AE SD (n = 2). In the spleen, percentages of all DC subsets are reduced by about half in san/san mice compared with +/+ animals, with the exception of CD8a + cDC, whose percentages remain similar, although not statistically significant (P ≤ 0.05). The drop in monocytes observed in the spleen could reflect inflammation-induced migration to blood, where levels of myeloid-derived cells are uncharacteristically high. Table 2 ). Monocyte and p-preDC populations are also detected. As with the spleen, there is an increased number of CD11c À cells, reflecting undifferentiated cells. The layout of cell populations in BM from Rag À/À mice was very similar to that in +/+ mice, suggesting no significant effect of the mutation on BM cell populations apart from the reduced number of L-DC (Fig. 5B ). This contrasts with spleen DC subset development, which must be dependent on T/B-derived haematopoietic factors. The populations present in Rag À/À MLN appear to be similar to those present in +/+ mice, except that the cDC populations have higher levels of CD11b expression (Fig. 5C ). Relative percentages of each subset are summarized in Table 2 . This shows that Rag À/À spleen contains only cDC and pDC, and no L-DC or mono- 
L-DC are absent in Rag
Discussion
This paper aims to further characterize L-DC on the basis of presence in lymphoid organs other than the spleen and the relative size of the cell population. In keeping with these aims, populations of cells matching L-DC marker expression were clearly present as distinct populations in spleen, blood and also BM, representing~6,~5 and 7% of all DC and monocytes in the spleen, blood and BM, respectively. Study of the steady-state function of L-DC is necessary to further characterize this unique subset. Moreover, the relationship between the populations identified in spleen and BM needs to be established. Based on evidence from long-term cultures, L-DC are spleen-derived cells, so it is important to establish the origin of the population identified in BM in terms of the site of development and the source of the precursor. Previous work in the laboratory has shown that in vitro culture of BM cells, probably containing HSC, over permissive spleen-derived stroma gives rise to L-DC [14] , reflecting the hypothesis that L-DC derive from HSC and are directed towards L-DC by the spleen stroma [15] . It remains to be seen if BM contains a similar L-DC-directing supportive cell line. Preliminary functional studies performed on both spleen-and BM-derived L-DC show that BM L-DC may have less capacity to activate T cells compared with spleen-derived L-DC.
In this paper, we investigated the presence of L-DC in lymphoid organs. It is also possible that these cells are present in tissue sites, such as the gut or the skin. Given the lack of L-DC in mesenteric lymph nodes, however, which drain the gut, it is unlikely that this subset is present at this site. Furthermore, previous studies have shown that L-DC lack langerin expression and are therefore not likely to be skin-related. The fact that L-DC are suggested to develop in the spleen from HSC in a specialized niche [15] suggests that the cells have a specialised role within this organ. Study of L-DC prevalence in other organs, however, is a possible direction of future investigations.
It is clear that L-DC represent a cell population distinct from cDC and pDC due particularly to their characteristically low CD11c and high CD11b expression. High levels of CD11b on the cell surface suggest that the cells are of myeloid origin. Their presence in the spleen could indicate a role in screening blood for either pathogen-related antigen or self-antigen. Indeed, their accessibility to blood-borne antigen is noted here to be far superior to other DC subsets. Whilst CD8a + cDC and fresh splenic CD11c + DC are known to be very good activators of both CD8 + and CD4 + T cells, neither could take up sufficient blood-borne antigen to induce proliferation of TCR-tg T cells in the experiment described here involving in vivo priming. In contrast, L-DC show a very strong T-cell activation response because of high accessibility to antigen as well as strong cross-presenting capacity in mice. Twelve week-old Rag À/À mice were obtained from the Animal Services Division (JCSMR). Spleen, bone marrow (BM), LN and thymus were isolated and cells prepared and stained as described in the legend to Figure 1 . A 12-week-old female C57BL/6J mouse was used as a +/+ control. Cross-hairs were set based on binding of isotype control antibodies and identifiable subsets of cells. Gates were set on the control and transferred to the plots of cells from two Rag À/À mice, with rectangular gates representing those transferred from the +/+ control, and circular gates identifying populations not present on the control plots. Live cells were gated using PI staining (data not shown), and CD11c the presence of LPS. The latter is a potent immunomodulatory molecule, signalling through toll-like receptor (TLR) 4 on some APC [16] . It is also likely that L-DC respond to activation through up-regulation of costimulatory molecules such as CD80, and production of cytokines, which are so far not defined for this subset [17] . Further studies involving in vitro activation of carefully isolated subsets by cell sorting will be needed to determine which cytokines are produced by L-DC in comparison with other DC subsets. Studies are still in progress to define a mutant mouse strain or a protocol, which gives numbers of cells suitable for more definitive studies of L-DC phenotype and function.
The exact location of L-DC in the spleen and how this location changes in the event of inflammation are still under investigation. This knowledge will almost certainly assist in determination of putative functions for L-DC. The lack of MHC-II surface expression on L-DC in the steady state is significant and could represent a tolerogenic role for these cells in the absence of inflammation. Alternatively, low MHC-II expression and high MHC-I expression [11] may indicate a CD8 + T cell-specific role for L-DC, for example through cross-presentation.
A cell phenotype of CD11c lo CD11b hi CD8a À MHC-II À could also be claimed to fit the phenotype of activated monocytes. Further analysis of size and marker expression, however, rules against this possibility, as it has been shown that L-DC express higher levels of MHC-I than monocytes and are able to activate CD8 T cells in our assays ( [11] and Fig. 3B) . Future studies will aim to determine markers and functions that serve to distinguish these cell types.
Given the predicted myeloid origin of L-DC indicated by the high level of CD11b expression, the existence of L-DC was examined in mutant mouse strains known to have perturbations in myelopoiesis. Mice lacking certain genes are a useful way to study cell development for two reasons. First, mutants could be a better source of cells either because of overproduction of the cell type in question or absence of other cell types. Secondly, a mutant mouse strain may be of interest if it specifically lacks the cell type of interest in terms of identifying developmental origins. The phenotypes of L-DC in the mutant mouse models sanroque and Rag À/À reflect the state expected because of the animal models. For example, L-DC in san/san animals show an up-regulation of CD8a and MHC-II expression, possibly reflecting activation of cells because of the constant inflammatory state induced by autoimmunity. In Rag À/À animals, by comparison, L-DC are not evident in the spleen, possibly reflecting an inability to develop in the absence of T-or B-cell-related factors. Crowley et al. [18] showed that although lymphocytes are generally not essential to the organization of the spleen and the presence of most DC subsets, lack of lymphocytes had a minor effect on marginal zone myeloid DC survival and maturation, which, they suggested, could be due to a lack of B cell-derived factors such as macrophage inflammatory factors a and b. This was reflected in our experiments, where we observed cDC populations in Rag-deficient mice, but report a lack of L-DC, which are thought to be of a myeloid origin. As we hypothesize that L-DC develop in the spleen [15] , it is likely that similar factors are necessary for L-DC development from spleen-resident HSC or progenitors. In both cases, the mutant strain of interest did not serve to provide higher numbers of L-DC required to perform a more complete analysis of their function. These experiments have demonstrated that the same L-DC are not present in the mutant strains investigated. The distribution and phenotypes of the DC subsets and monocytes identified, however, are indicative of the known characteristics of each mutant. For example, L-DC in the spleen of san/san animals could have an inflammatory phenotype, whilst more undifferentiated myeloid cells are present in spleen of Rag À/À animals.
Conclusion
From these experiments, it is evident that L-DC represent a small but distinct subset of dendritic-like cells in the spleen. A similar cell type is also present in BM, although future studies will need to determine whether they represent the same subset. Although the function of L-DC is still under investigation, it is thought that they reflect a unique subset that will demonstrate unique function specific to their predominant location in spleen and blood.
